Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMG5MJL)

Drug Name

Phosphoric acid monotetradecyl ester Drug Info

Synonyms

Tetradecyl dihydrogen phosphate; UNII-DF6HW7A5EB; 1-Tetradecanol, dihydrogen phosphate; 10054-29-2; Phosphoric acid monotetradecyl ester; DF6HW7A5EB; CHEMBL187633; 69029-24-9; myristyl phosphate; EINECS 233-184-8; AC1Q6T1O; SCHEMBL375578; AC1L336V; Phosphoric acid tetradecyl ester; DTXSID1073995; BDBM50170842

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 82327
CAS Number: CAS 10054-29-2
TTD Drug ID: DMG5MJL

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Preclinical Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Lysophosphatidic acid receptor 1 (LPAR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SAR-100842	DMDMQW0	Fibrosis	GA14-GC01	Phase 2	[2]
BMS-986020	DMHMV6E	Scleroderma	4A42	Phase 2	[3]
BMS-986278	DMD27RW	Pulmonary fibrosis	CB03.4	Phase 2	[4]
BMS-986337	DM9GC6L	Pulmonary fibrosis	CB03.4	Phase 1	[5]
BMS-986202	DM8TAI9	Idiopathic pulmonary fibrosis	CB03.4	Preclinical	[6]
LPA	DMI5XR1	Discovery agent	N.A.	Investigative	[7]
Ki16425	DMJTDK9	Discovery agent	N.A.	Investigative	[8]
dioctanoylglycerol pyrophosphate	DM0QY1V	Discovery agent	N.A.	Investigative	[9]
2-oleoyl-LPA	DMN9OS1	Discovery agent	N.A.	Investigative	[10]
dodecyl-thiophosphate	DMAJVPI	Discovery agent	N.A.	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Lysophosphatidic acid receptor 1 (LPAR1)	TTQ6S1K	LPAR1_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30.
2	Promising Pharmacological Directions in the World of Lysophosphatidic Acid Signaling. Biomol Ther (Seoul) 2015 January; 23(1): 1-11.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA(1)) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). BMJ Open Respir Res. 2021 Dec;8(1):e001026.
5	ClinicalTrials.gov (NCT04550195) A Double-Blind, Placebo-Controlled, Randomized, Single and Multiple Ascending Dose Study of the Safety and Tolerability, and Pharmacokinetics (Including Food Effect, pH Effect and Japanese Bridging Study) of BMS-986337 Following Oral Administration in Healthy Participants. U.S.National Institutes of Health.
6	Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. J Pharmacol Exp Ther. 2011 Mar;336(3):693-700.
7	Diversity of lysophosphatidic acid receptor-mediated intracellular calcium signaling in early cortical neurogenesis. J Neurosci. 2010 May 26;30(21):7300-9.
8	Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis. Int J Oncol. 2012 Apr;40(4):1133-41.
9	Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol Pharmacol. 2001 Oct;60(4):776-84.
10	Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors. FEBS Lett. 2000 Jul 28;478(1-2):159-65.